Market Overview

Geron Shares Rally Following Positive Results from Phase 2 Study of Imetelstat

Related GERN
Morning Market Movers
Midday Gainers From November 14: Geron, Pandora Media, Bitauto, IAMGOLD

Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial. To view the presentation slides, please visit www.geron.com/PDFs/Geron-Imetelstat-ETPh2-ASH-2012.pdf.

Posted-In: News FDA Movers

 

Related Articles (GERN)

Around the Web, We're Loving...

Get Benzinga's Newsletters